Table 1 |
|||||||
|
Characteristics of patients in the study |
|||||||
|
Patient |
Ethnicity |
HLA-DRB1 genotype |
ACPA |
Disease duration (years) |
Treatment |
C-reactive proteina (mg/l) |
Representation |
|
|
|||||||
|
RA1 |
Caucasian |
03,0401 |
+ |
6 |
M, S |
8 |
Figure 1 |
|
RA2 |
Caucasian |
03, 0401 |
+ |
< 1 |
Nil |
3 |
Figures 1 to 5 |
|
RA3 |
Caucasian/Pacific Islander |
0403, 0405 |
- |
< 1 |
M, S, H |
3 |
Figure 1 |
|
RA4 |
Caucasian |
0401, 0404 |
+ |
< 1 |
L |
11 |
Figures 1 to 5 |
|
RA5 |
Caucasian |
0404, 1302 |
+ |
1 |
M, S, H |
2 |
Figure 1 |
|
RA6 |
Caucasian |
0401 13 |
+ |
> 5 |
M, H |
1 |
Figures 1 to 5 |
|
RA7 |
Asian |
0405 |
- |
1 |
M |
1 |
Figures 1 to 5 |
|
RA8 |
Caucasian |
0401, 0404 |
+ |
> 5 |
L, H, S |
22 |
Figures 1 to 5 |
|
RA9 |
Caucasian |
0103, 0101 |
+ |
< 1 |
Nil |
4 |
Figures 1 to 5 |
|
RA10 |
Caucasian |
01, 1302 |
+ |
5 |
H |
10 |
Figures 1 to 5 |
|
RA11 |
Caucasian |
04, 0301 |
- |
4 |
M, S, H |
3 |
Figures 1 to 5 |
|
RA12 |
Caucasian |
0401 |
+ |
0 |
Nil |
45 |
Figures 1 to 5 |
|
RA13 |
Caucasian |
0101, 1301 |
- |
> 5 |
M |
20 |
Figures 1 to 6 |
|
RA14 |
Caucasian |
0408, 11 |
+ |
> 5 |
M, S, H |
4.6 |
Figures 1 to 6 |
|
RA15 |
Caucasian |
0401, 0408 |
+ |
0 |
Nil |
1 |
Figures 1 to 6 |
|
RA16 |
Caucasian |
0101, 0408 |
+ |
0 |
Nil |
6 |
Figures 1 to 6 |
|
RA17 |
Caucasian |
0401, 03 |
+ |
> 5 |
M, A |
33 |
Figure 6 |
|
RA18 |
Caucasian |
0401, 03 |
+ |
3 |
M |
2 |
Figures 1 to 5 |
|
RA19 |
Caucasian |
0101, 0103 |
+ |
2 |
M, S, H |
5.3 |
Figures 1 to 5 |
|
RA20 |
Caucasian |
0401, 1501 |
+ |
2 |
- |
9.9 |
Figures 1 to 5 |
|
RA21 |
Caucasian |
0401, 0101 |
+ |
> 5 |
M, P |
2 |
Figures 1 to 5 |
|
HC1 |
Caucasian |
01 |
- |
Figures 1 to 5 |
|||
|
HC2 |
Caucasian |
03, 04 |
- |
Figures 1 to 5 |
|||
|
HC3 |
Caucasian |
0401, 0701 |
- |
Figures 1 to 5 |
|||
|
HC4 |
Caucasian |
0101, 08 |
- |
Figures 1 to 5 |
|||
|
HC5 |
Caucasian |
1301, 0401 |
- |
Figures 1 to 6 |
|||
|
HC6 |
Caucasian |
0401, 1301 |
- |
Figures 1 to 6 |
|||
|
|
|||||||
|
A, abatacept; ACPA, anti-citrullinated peptide antibody; H, hydroxychloroquine; L, leflunomide; M, methotrexate; S, sulfasalazine; P, prednisone. For rheumatoid arthritis (RA) patients, mean age is 50 (range 22 to 65), 90% female; for healthy control (HC) individuals, mean age is 38 (40 to 45), 50% female. aMeasured at the time of blood withdrawal for peptide response. |
|||||||
|
Law et al. Arthritis Research & Therapy 2012 14:R118 doi:10.1186/ar3848 |
|||||||
